Citations

Clear

6273 citation(s) found for "To, Andrew".

92. Can We Innovate the Teaching of Facial Anatomy for Aesthetic Surgery Using 3D Photogrammetry and Immersive Virtual Reality
Hussein, Sara , Emanuels, Andrew F., Leonel, Luciano, Lachman, Nirusha , Celda, María Peris, Sheahan, Eric M., Martinez, Erick O., Emanuels, Andrew, Morris, Jonathan M. , Martinez, Erick O., Hanson, Christian R., Sharaf, Basel

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | April 25, 2025 | Volume: 13 | Issue: S1 | Pages: 64-64

10.1097/01.gox.0001112320.62413.e9 Get It

Consensus nomenclature and abbreviation for anti-synthetase syndrome: an IMACS project
Aggarwal, Anushka , Chandra, Tanya , Keret, Shiri , Pauling, John D , Shamim, Ejaz A. , Miller, Fredrick W., Mammen, Andrew L. , Sambataro, Gianluca , Castañeda, Santos , Dimachkie, Mazen M. , Katsumata, Yasuhiro , Mozaffar, Tahseen , Gunawardena, Harsha , Moghadam‐Kia, Siamak , Ladha, Parth, Mittal, Srijan, Haldule, Saloni , Edpuganti, Namratha , Sridhar, Shreya , Savaliya, Rutvik, Batra, Vanshita, Liewluck, T , Fernandez, Anthony P , Bartoloni, Elena , Shinjo, Samuel Katsuyuki , Katsumata, Yasuhiro , Fujimoto, Manabu , Lilleker, James B , Mozaffar, Tahseen , Rojas Serrano, Jorge , Edpuganti, Namratha , Aggarwal, Rohit , Pauling, John D , Dimachkie, Mazen M , Bonella, Francesco , Liewluck, Teerin , Shinjo, Samuel Katsuyuki , Werth, Victoria P. , Campanilho‐Marques, Raquel , Selva-O’Callaghan, Albert , Mann, H. , Cavagna, Lorenzo , Oddis, Chester V. , Mittal, Srijan, Aggarwal, Rohit

Mayo Clinic

Rheumatology | April 25, 2025 | Volume: 64 | Issue: 9 | Pages: 4930-4936

10.1093/rheumatology/keaf229 | PMID 40286313 Get It

Abstract Objectives The lack of uniform terminology and abbreviations for anti-synthetase syndrome has led to significant challenges in research and clinical practice. This study aimed to establish an international consensus on a standardized nomenclature and abbreviation among a diverse group of global myositis experts and patient representatives. Methods This qualitative project was approved by the International Myositis Assessment and Clinical Studies Group (IMACS). Based on the outcomes of a literature review and preliminary survey, list of terms for nomenclature and abbreviations was finalized. Subsequently, two rounds of the Delphi survey were conducted among myositis experts and patient participants to ascertain current practices and preferences. Using Nominal Group Technique (NGT), the project steering committee developed a consensus nomenclature and abbreviation. Results A total of 241 and 132 myositis experts from six continents, 35 countries and 9 specialities participated in round 1 and round 2 of the Delphi survey, respectively. The results indicated a preference for the terms anti-synthetase syndrome, antisynthetase syndrome and anti-tRNA synthetase syndrome. The abbreviations ASS, ASyS and ASSD were most used, though ASS received notable disapproval. The steering committee, including twenty-five myositis experts and three patient representatives from diverse backgrounds and geographical locations, reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and ASyS as the preferred abbreviation, with 100% and 93.1% votes, respectively. Conclusion The terms anti-synthetase syndrome and ASyS should be adopted as the standard nomenclature and abbreviation in both research and clinical practice. This standardization is expected to increase consistency within the literature.
Risk of Post-Polypectomy Bleeding After Colorectal Endoscopic Mucosal Resection in Patients with Chronic Kidney Disease: A Propensity-Matched Analysis of the US Collaborative Network
Patel, Feenalie N. , Ramai, Daryl , Sr, Khaled, Shaik, Danial H., Thakkar, Shyam , Rex, Douglas K. , Beran, Azizullah , Elfert, Khaled , Mohamed, Mouhand , Canakis, Andrew , Sr, Khaled, Bhavsar‐Burke, Indira , Guardiola, John J.

Mayo Clinic

No container title available | April 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6398416/v1 Get It

Abstract Background Studies evaluating the risk of post-polypectomy bleeding (PPB) after colorectal endoscopic mucosal resection (EMR) in patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) are limited. Methods This retrospective cohort study utilized the U.S. Collaborative Network to assess the risk of PPB after colorectal EMR in patients with CKD compared to controls. Using one-to-one propensity score matching (PSM), the primary outcome measured was PPB within 30 days after colorectal EMR. The PPB risk was further stratified by CKD severity: non-advanced CKD and advanced CKD. Results After PSM, each cohort included 7,460 patients. Overall, CKD was associated with increased risk of PPB following colorectal EMR (5.5% vs. 4%, odds ratio [OR] 1.38, 95% confidence interval [CI] 1.19–1.61, p < 0.001). The PPB risk was significantly higher in patients with advanced CKD (8.1% vs, 4.6%, OR 1.83, 95% CI 1.43–2.34, p < 0.001), while those with non-advanced CKD showed modest increase in risk of PPB (4.7% vs. 3.9%, OR 1.21, 95% CI 1.001–1.46, p = 0.049). Conclusion Patients with CKD had higher risk of PPB than patients without CKD, but absolute risk remained low. The PPB risk was notably increased in patients with advanced CKD. Optimizing patients with CKD, especially advanced CKD, before colorectal EMR and monitoring for post-procedure bleeding remains important.
Dilated Cardiomyopathy Evaluation with Imagenomics: Combining Multimodal Cardiovascular Imaging and Genetics
Galanti, Kristian , Dabbagh, Ghaith Sharaf , Ricci, Fabrizio , Gallina, Sabina, Giansante, Roberta , Jacob, Ron , Obeng‐Gyimah, Edmond, Prasad, Sanjay , Birnie, David H. , Landstrom, Andrew P. , Mohammed, Selma F. , Landstrom, Andrew P , Mohammed, Selma , Mohiddin, Saidi , Khanji, Mohammed Yunus , Chahal, Choudhary Anwar A , Sharaf Dabbagh, Ghaith , Ricci, Fabrizio , Gallina, Sabina , Jacob, Ron, Cooper, Leslie T. , Prasad, Sanjay K , Khanji, Mohammed Y , Chahal, C. Anwar A.

Mayo Clinic

ESC Heart Failure | April 25, 2025 | Volume: 12 | Issue: 4 | Pages: 2669-2690

10.1002/ehf2.15307 | PMID 40275589 Get It

Abstract Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by the presence of left ventricular dilatation and systolic dysfunction unexplained by abnormal loading conditions or coronary artery disease. However, a broad range of phenotypic manifestations, encompassing isolated scar, DCM with preserved ejection fraction, and overt DCM, should be regarded as a diagnostic classification representing a broad spectrum of underlying aetiologies, including both inherited and acquired heart muscle disorders. A multimodal non-invasive imaging approach is essential for accurate morpho-functional assessment of cardiac chambers and is key to establish the cardiac phenotype and to rule out an underlying ischaemic aetiology. Furthermore, advanced imaging techniques enable deep cardiovascular phenotyping and non-invasive tissue characterization. The aim of this review is to propose a systematic approach to the diagnosis of DCM, emphasizing the importance of genetics and clinical findings for a precise and practical clinical approach. Also, we strive to qualify the role of cardiac imaging in the diagnosis of DCM, particularly on the relevance of novel techniques and clinical utility of actionable parameters to improve current diagnostic schemes and risk stratification algorithms. We further elaborate on the role of cardiac imaging to deliver optimal guidance to aetiology-based therapeutic approaches, verification of treatment response and disease progression monitoring.
Safety and efficacy of continuous infusion terlipressin (BIV201): A phase 2 trial in patients with decompensated cirrhosis and refractory ascites
Bajaj, Jasmohan S. , Reddy, K. Rajender , Keaveny, Andrew P. , Porayko, Michael K. , Koch, David , Thuluvath, Paul J. , Angeli, Paolo, Janardhan, Sujit , Zhang, Jeffrey , Clausen, Susan, Dauphinée, Elisa, Palumbo, Joseph, Markham, Penelope , Weinberg, Ethan M , Rajender Reddy, K , Keaveny, Andrew P , Porayko, Michael K , Koch, David , Angeli, Paolo , Orman, Eric S , Palumbo, Joseph M , Weinberg, Ethan M. , Simonetto, Douglas A. , Angeli, Paolo , Orman, Eric S. , Clausen, Susan

Mayo Clinic

Liver Transplantation | April 24, 2025 | Volume: 31 | Issue: 10 | Pages: 1202-1214

10.1097/lvt.0000000000000623 | PMID 40272365 Get It

Refractory ascites often requires therapeutic paracentesis, which is associated with potential risks and diminished quality of life. Terlipressin is a vasopressin analog that is indicated for i.v. bolus injection for hepatorenal syndrome, with the potential to reduce large-volume ascites and its complications. Continuous infusion of terlipressin is associated with fewer adverse effects than bolus dosing. The efficacy and safety of continuous infusion of a novel liquid formulation of terlipressin acetate (BIV201) were evaluated in this open-label phase 2 study. Patients with cirrhosis and refractory ascites were randomly assigned (2:1) to receive two 28-day cycles of continuous infusion BIV201 plus standard of care (SOC) separated by a ≤56-day washout (n=10), or SOC alone (n=5). Data analysis was limited by the small sample size and confounded by a potential interaction with gabapentinoids in the BIV201+SOC group. Nonetheless, there were differences in favor of BIV201+SOC versus SOC in the coprimary efficacy endpoints and several quality of life assessments. The beneficial effects of BIV201 on liver complications (mean: 90% CI; BIV201-completers=2.87: 1.51; 5.46 vs. SOC=2.38: 1.20; 4.73) and the change in cumulative ascites (mean: 90% CI; BIV201-completers=−10.76: −26.51; 5.00 vs. SOC=−4.99: −21.95; 11.97) were more pronounced versus SOC in the 5 BIV201+SOC patients who completed both treatment cycles. There were also greater improvements in exploratory quality of life assessments and the percent change in therapeutic paracenteses with BIV201+SOC (−27.94±41.80) versus SOC (−16.67±45.64). Despite the high rate of hyponatremia in the BIV201+SOC group (4/10 patients), the safety profile suggested that continuous BIV201 infusion was well tolerated. These findings support further development of BIV201 in confirmatory trials.
Relationships between smart ring-measured sleep variables and next-day basketball game performance: A case series
Fields, Jennifer B. , Hahn, Joseph, King, Erica L. , Allen, Leah, Horlock, Conor F., Jones, Margaret T. , Fields, Jennifer B , Jagim, Andrew R. , Allen, Leah

Mayo Clinic

International Journal of Sports Science & Coaching | April 24, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/17479541251334461 Get It

Sleep is critical to athlete health and sport performance. Purpose To evaluate the relationship between objective sleep data and next-day basketball game performance. Methods Collegiate men basketball athletes (n = 4) wore smart ring sleep trackers the night before games (n = 22). Sleep variables included hours of total sleep (TS), rapid eye movement sleep duration (RM), deep sleep duration (DS), and heart rate variability (HRV). Game performance was evaluated using field goal percentage (FG%) and player efficiency (EFF). Results TS, RM, DS, and HRV demonstrated very weak relationships with FG% ( p > 0.05) and EFF ( p > 0.05). Individual player analysis revealed one athlete exhibited strong to moderate correlations for TS-EFF (r = 0.67), RS-EFF (r = 0.41), TS-FG% (r = 0.51), and RM-FG% (r = 0.67) ( p < 0.05). Sleep metrics had no effect on FG% (R 2 = 0.025) and EFF (R 2 = 0.053) ( p > 0.05). Conclusions Results suggest a lack of group-level associations between smart ring-measured sleep variables and next-day game performance. This highlights the need for individualized sleep monitoring rather than relying solely on objective metrics.
Rare Extra‐Axial Chordoma of the Anteromedial Thigh: A Case Report
Tibbo, Meagan E. , Mysore, Nishad , Jose, Jean , Temple, H. Thomas , Rosenberg, Andrew E.

Mayo Clinic

Clinical Case Reports | April 23, 2025 | Volume: 13 | Issue: 4 | Pages: No page available

10.1002/ccr3.70341 | PMID 40270777 Get It

ABSTRACT Chordomas are rare notochordal malignancies typically occurring in the axial skeleton. Less than 100 extra‐axial chordomas have been reported. We describe a unique chordoma of the anteromedial thigh. The clinical presentation of extra‐axial chordomas is highly variable; thus, recognizing this entity in the differential diagnoses of extra‐axial bone/soft tissue tumors is important.
Abstract 166: Spatial subtypes and cellular interactions of cancer-associated fibroblasts revealed by single-cell spatial omics
Zhang, Yuanyuan , Liu, Yang , Wang, Ruiping , Pei, Guangsheng , Cho, Kyung Serk , Basi, Akshay , Rajapakshe, Kimal , Chu, Yanshuo , Jiang, Jiahui , Zhang, Daiwei , Yan, Xinmiao , Guerrero, Paola A. , Li, Mingyao , Hwang, Tae Hyun , Futreal, P. Andrew , Soto, Luisa M. Solis , Kadara, Humam , Liu, Yunhe , Sinjab, Ansam F. , Min, Jimin , Han, Guangchun , Paradiso, Francesca , Dai, Enyu , Burks, Jared K , Serrano, Alejandra G. , Ajani, Jaffer A. , Jazaeri, Amir Anthony , Maitra, Anirban , Wang, Linghua

Mayo Clinic

Cancer Research | April 22, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 166-166

10.1158/1538-7445.am2025-166 Get It

Abstract Background: Cancer-associated fibroblasts (CAFs) are a highly diverse cell population that plays a crucial role in shaping the tumor microenvironment (TME). Their spatial interactions within the TME remain to be systematically characterized, and the factors driving their phenotypic heterogeneity are not yet fully understood. Recent advancements in single-cell spatial transcriptomics technologies and cell segmentation approaches enable the precise measurement of thousands of transcripts at subcellular resolution. Combined with innovative bioinformatics, these advancements have unlocked unprecedented opportunities for in-depth characterization of CAFs and their interactions within the TME. Methods: We conducted a comprehensive spatial transcriptomic analysis of CAFs across 8 cancer types, using the CosMx and MERSCOPE platforms to profile nearly 6 million cells as part of our discovery cohorts. We developed a novel computational method to spatially cluster CAF subpopulations and defined four distinct spatial CAF subtypes. We further examined their phenotypic differences, spatial niche organization, and interactions with neighboring cells. Additionally, we investigated the influence of CAF subtypes on immune cell phenotypes and infiltration levels. To validate our findings, we employed multiple spatial platforms, including Visium, Xenium, COMET, CODEX, and IMC, to ensure reproducibility across diverse technologies. Moreover, we performed correlative studies in large-cohorts with rich clinical data to evaluate the clinical significance of these CAF subtypes. Results: Our approach provided an unprecedented high-resolution examination of the spatial phenotypes of CAFs in large, complex tissues, uncovering novel insights. We comprehensively characterized CAFs across various solid tumor types and identified four conserved spatial CAF subtypes. These subtypes are characterized by distinct cell organizational patterns, neighboring cell compositions, interaction networks, and transcriptomic features. Moreover, they demonstrate significant correlations with the abundance, distribution, and phenotypes of tumor-infiltrating immune cells, as well as associations with tumor histopathological features and clinical outcomes. Conclusions: Our study provides a pan-cancer, high-resolution characterization of CAF spatial organization and interactions in solid tumors and identified conserved spatial CAF subtypes linked to distinct organizational patterns. Our findings reveal that the transcriptomic states and phenotypes of CAFs are significantly shaped by their interactions with neighboring cancer and immune cells. Beyond offering novel insights into the spatial heterogeneity of CAFs, this work paves the way for developing strategies to effectively target and modulate CAFs for therapeutic benefit. Citation Format: Yunhe Liu, Ansam Sinjab, Jimin Min, Guangchun Han, Francesca Paradiso, Yuanyuan Zhang, Yang Liu, Ruiping Wang, Guangsheng Pei, Kyung Serk Cho, Enyu Dai, Akshay Basi, Jared K. Burks, Kimal I. Rajapakshe, Yanshuo Chu, Jiahui Jiang, Daiwei Zhang, Xinmiao Yan, Paola A. Guerrero, Alejandra Serrano, Mingyao Li, Tae Hyun Hwang, Andrew Futreal, Jaffer A. Ajani, Luisa M Solis Soto, Amir A. Jazaeri, Humam Kadara, Anirban Maitra, Linghua Wang. Spatial subtypes and cellular interactions of cancer-associated fibroblasts revealed by single-cell spatial omics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 166.
Abstract 7344: Family history of hematologic malignancy and prognosis across lymphoma subtypes: Novel association with poor outcomes in follicular lymphoma
Cholack, George , Mwangi, Raphael , Hinder, Verena, Griffen, Rosalie, Robinson, Dennis P. , Feldman, Andrew L., Ansell, Stephen M. , Thompson, Carrie A. , Novak, Anne J. , Cholack, George A , Habermann, Thomas M. , Hinder, Verena, Feldman, Andrew L. , Witzig, Thomas E. , Link, Brian K. , Wang, Yucai , Slager, Susan L. , Maurer, Matthew J. , Cerhan, James R.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 7344-7344

10.1158/1538-7445.am2025-7344 Get It

Abstract Family history of hematologic malignancy (FHHM) is an established risk factor for developing lymphoma, but studies examining associations between self-reported FHHM and lymphoma prognosis during the recent treatment era are limited. Utilizing a prospective cohort study, we evaluated associations between FHHM and prognosis for common lymphoma subtypes, including diffuse large B-cell (DLBCL), follicular (FL), marginal zone (MZL), mantle cell (MCL), Hodgkin (HL), and T-cell (TCL) lymphomas. We used the Mayo Clinic component of the Molecular Epidemiology Resource, a prospective cohort study of newly diagnosed lymphoma patients enrolled from 2002 to 2015. Self-reported FHHM (HL, NHL, leukemia, or multiple myeloma) in a first-degree relative was obtained via questionnaire. Primary outcomes were overall survival (OS) and event-free survival (EFS; time from diagnosis to disease progression, initiation of second-line therapy, or all-cause death). Secondary outcomes were failure to achieve 24 months of event-free survival (EFS24; associated with aggressive disease and poor outcomes) and lymphoma-specific survival (LSS; time from diagnosis to death from lymphoma or lymphoma treatment-related complications). We used multivariable Cox proportional hazards regression to estimate hazard ratios (HRs) and 95% confidence intervals (CI) for the association of FHHM with OS, EFS, and LSS, and logistic regression to estimate odds ratios (ORs) and 95% CI for the association with failure to achieve EFS24. All models were adjusted for sex and a lymphoma subtype specific prognostic index. The cohort consisted of 650 DLBCL, 679 FL, 291 MZL, 178 MCL, 254 HL, and 196 TCL patients. The prevalence of FHHM ranged from 9.7% in TCL to 14% in FL. FHHM was not associated with OS in any subtype, but MCL patients with FHHM showed an inferior EFS (HR=1.70, 95% CI 1.02-2.85; p=0.04). For EFS24, FHHM was associated with failure to achieve EFS24 only in FL (OR=1.57, 95% CI 0.99-2.48; p=0.05). Similarly, FHHM was associated with inferior LSS in FL patients (HR=1.98, 95% CI 1.11-3.53; p=0.02). In a treatment subgroup analysis of FL patients, the FHHM associations with failure to achieve EFS24 (OR=2.48, 95% CI 1.04-5.74; p=0.04) and inferior LSS (HR=2.68, 95% CI 1.09-6.58; p=0.03) strengthened among those treated with frontline immunochemotherapy (IC). In summary, there were no evidence of associations between FHHM and OS across lymphoma subtypes, but MCL patients with FHHM displayed inferior EFS. FL patients with FHHM were more likely to not achieve EFS24 and to ultimately die of their lymphoma or a lymphoma treatment-related complication. This finding was stronger in more aggressive FL requiring frontline IC. This novel finding would suggest that genetic or environmental factors associated with FHHM may underlie pathways that impact disease aggressiveness and early clinical failure in FL. Citation Format: George Cholack, Raphael Mwangi, Thomas M. Habermann, Verena Hinder, Rosalie Griffen, Dennis Robinson, Andrew L. Feldman, Thomas E. Witzig, Stephen M. Ansell, Brian K. Link, Yucai Wang, Carrie A. Thompson, Susan L. Slager, Matthew Maurer, Anne J. Novak, James R. Cerhan. Family history of hematologic malignancy and prognosis across lymphoma subtypes: Novel association with poor outcomes in follicular lymphoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7344.